Get started
Author

Melissa Rowe

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
2025 · Saad Z. Usmani, Thierry Facon, et al. · Nature Medicine · 149
PDF
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
2024 · Philippe Moreau, Cyrille Hulin, et al. · The Lancet Oncology · 132
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
2025 · Jill Corre, Laure Vincent, et al. · Blood · 29
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
2023 · Loretta J. Nastoupil, Georg Hess, et al. · Blood Advances · 28
PDF
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
2024 · Sonja Zweegman, Thierry Facon, et al. · Blood · 13
OA-63 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
2024 · Saad Z. Usmani, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia · 8
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
2025 · Saad Z. Usmani, Thierry Facon, et al. · Nature Medicine · 7
PDF
Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load
2025 · Cathelijne Fokkema, Luca Bertamini, et al. · Blood · 4
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study.
2025 · Thierry Facon, Sonja Zweegman, et al. · Journal of Clinical Oncology · 3
Efficacy of Daratumumab-Bortezomib-Lenalidomide-Dexamethasone (DVRd) vs Daratumumab-Lenalidomide-Dexamethasone (DRd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
2025 · Saad Usmani, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
POSTER: MM-739 Daratumumab + Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) vs VRd in Transplant-Ineligible (TIE)/Transplant-Deferred (TD) Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 CEPHEUS Trial Cytogenetic Subgroup Analysis
2025 · Saad Z. Usmani, Nizar J. Bahlis, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.
2026 · Saad Z. Usmani, Thierry Facon, et al. · Journal of Clinical Oncology · 1
Patient-Reported Outcomes (PROs) and Safety in Patients (Pts) With NDMM Achieving MRD Negativity and ≥CR (MRDneg) in the Phase 3 PERSEUS and CEPHEUS Trials
2025 · Jesús San-Miguel, Saad Usmani, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Dynamic Frailty Analysis of Transplant-Ineligible (TIE) Patients with NDMM in the Phase 3 MAIA and CEPHEUS Trials of Daratumumab (Dara) + Lenalidomide-Dexamethasone (Rd) and Bortezomib-Rd (VRd)
2025 · Hira Mian, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysis.
2025 · Nizar J. Bahlis, Saad Z. Usmani, et al. · Journal of Clinical Oncology · 1
PDF
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS
2026 · Saad Z. Usmani, Thierry Facon, et al. · Journal of Clinical Oncology
PDF
OA-01 5-Year Sustained Minimal Residual Disease (MRD) Negativity and Survival with Daratumumab Maintenance (D-maint) in Transplant-Eligible (TE) NDMM: CASSIOPEIA Registry
2026 · Jill Corre, Pieter Sonneveld, et al. · Clinical Lymphoma Myeloma & Leukemia
OA-69 The Benefit of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (DVRd) on Depth and Durability of Response in the Phase 3 CEPHEUS Trial: Updated Minimal Residual Disease Analysis
2026 · Sonja Zweegman, Nizar J. Bahlis, et al. · Clinical Lymphoma Myeloma & Leukemia
LBA-07 Long-Term Outcomes With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) Versus VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) in the Phase 3 PERSEUS Study
2026 · Pieter Sonneveld, Mario Boccadoro, et al. · Clinical Lymphoma Myeloma & Leukemia
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS
2026 · Sonja Zweegman, Saad Z. Usmani, et al. · Leukemia
PDF
POSTER: MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study
2026 · Saad Z Usmani, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study
2026 · Meletios A Dimopoulos, Carolina Terragna, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-338: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study
2026 · Saad Z Usmani, Thierry Facon, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-326: New IMS/IMWG Consensus Genomic Staging Risk Criteria by Next-Generation Sequencing: Analysis of Daratumumab Benefit in Both High- and Standard-Risk Patients in the PERSEUS/EMN017 Study
2026 · Meletios A Dimopoulos, Carolina Terragna, et al. · Clinical Lymphoma Myeloma & Leukemia
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS
2026 · Sonja Zweegman, Thierry Facon, et al. · Blood Advances
Works count: 41
Citation count: 381
H-index: 7
I10-index: 5
Year
Topic
Type